VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic

VOLITIONRX LTD

2025-Q3 EPS reported -$0.17 revenue$1,280,350

Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
Net cash used in ops $3.6M (-33% YoY); post-quarter raised $6.1M net from public offering.
Signed Research License and Option Agreement for APS with Werfen; Co-Marketing Agreement with Hologic.
In discussions with ~10 leading diagnostic/liquid biopsy companies for further licensing deals.
Anticipates peer-reviewed publications on Nu.Q platform and Capture-Seq technology.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.